Company presentation
July 2020 2
Forward looking statements
This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.
Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.
Camurus undertakes no obligation to update forward-looking statements Long-acting medications addressing key healthcare challenges 4
Corporate highlights
Rapidly growing commercial Broad late-stage pipeline stage company • 10 innovative clinical programs in • Fully operational commercial addiction, pain, oncology, endocrine infrastructure in Europe and Australia disorders and CV diseases • Buvidal® to date launched in 8 countries • Two ongoing Phase 3 studies • Strong growth of product • Advancing early stage opportunities
Market approvals Unique FluidCrystal® Partnerships Positive 2020 outlook Weekly and monthly nanotechnologies R&D collaborations, Expected FY net revenues* ® Buvidal for opioid • New generation long-acting licensing and royalty SEK 340 - 380 million dependence depot technology arrangements with whereof product sales • Validated in +20 clinical trials pharma and biotech SEK 310 - 340 million companies and by approved products *excluding a $35 million milestone for final FDA approval of Brixadi™in the US
LISTED ON NASDAQ STO; TICKER CAMX MARKET CAP ~ SEK 7.6 billion EMPLOYEES: 130 HQ: Lund, Sweden REGIONAL OFFICES: Cambridge, Mannheim, Sydney 5 Camurus‘ FluidCrystal® long-acting release technology has unique properties
Easy and convenient administration Adopted to prefilled syringes and autoinjectors Rapid onset & long-acting release Manufacturing by standard processes Applicable across substance classes Strong intellectual property
Injection of liquid . formulation Encapsulating Slow release Drug release and conc using prefilled H2O liquid crystal gel of drug biodegradation of
syringe or triggered by blood gel matrix to full
autoinjector water uptake drug resolution time
Sources: Tiberg F, et al. Chapter in Long Acting Injections and Implants, Advances in Delivery Science and Technology 2012; Tiberg F, et al. OnDrugDelivery 2010; Tiberg F, et al. Drug Del. Sci. Tech., 21 (1) 101-109 2011. 6
FluidCrystal – Long-acting release
Immediate release pasireotide (Signifor®) Pasireotide FluidCrystal® (CAM4071)
10 10 Pasireotide IR 600 ug (SC Pasireotide FluidCrystal 20 thigh, n = 94) mg (SC thigh, n = 12)
1 1 pasireotide plasma concentration (ng/mL) concentration plasma pasireotide pasireotide plasma concentration (ng/mL) concentration plasma pasireotide 0,1 0,1 0 7 14 21 28 0 7 14 21 28 Time (days) Time (days) 7 Opioid dependence – escalating global health crisis
• Largest society burden of all drugs1 Mounting opioid overdose deaths2 1 64 30 • 35 million opioid users worldwide -
Scotland • High need for better access to care 25
and new treatment alternatives USA 20 • Investment in treatment brings substantial value and saves lives 15
10 Australia • Significant limitation with current daily Sweden medications UK 5 Finland ‒ Diversion, misuse, overdosing, poor retention, Germany burdens and stigma of daily buprenorphine and 0 methadone medications Drug overdose deaths per 100,000, age group 15 #1 cause of death for people under 50 in the US2,3 Recent US life expectancy decline largely due to opioids4
Sources: 1UNODC, World Drug Report 2019; 2.EMCDDA 2018, National Records of Scotland, Centers for Disease Control and Prevention 3Frazier at al, 2017, Journal of the American Medical Association; 4Crow D. Financial Times.com, accessed on March 13, 2018, https://www.ft.com/content/d22e742c-e65c-11e7-97e2-916d4fbac0da 8
Buvidal® – flexible long-acting treatment of opioid dependence
Flexible-dose, weekly and monthly, subcutaneous buprenorphine for treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over1
Launch initiated in Europe and Australia in 2019
Source: 1Buvidal Summary of Product Characteristics (SmPC), 2018 9 Buvidal provides significant benefits to patients and society
• Improved treatment outcomes and patient satisfaction1,2 • Reduced treatment burden and stigma3 • Diminished diversion, misuse and pediatric exposure4 • Reduced treatment costs in the criminal justice system5
“CAM2038 compared to my previously prescribed sublingual buprenorphine treatment” “For me, Buvidal is a Much better 83% revelation. I know that as Slightly better POSITIVE long as I stay on Buvidal 1 I’ve got a chance” About the same N=133 Sophie, Buvidal patient in Wales Slightly worse
Much worse
1. Frost et al, Addiction, 2019;114(8):1416-1426; 4. EPAR 10
Accelerating uptake of Buvidal
•Launched in 8 markets since 2019 •Increasing product sales 7,500 patients in treatment with MSEK Buvidal at the end of March 2020 60 Market leader in Finland and Norway* Rapid growth in Australia with an 50 48.6 estimated 3,000 patients on Buvidal Accelerating uptake in Sweden, 40 +60% Germany, UK and Denmark 30.3 Covid-19 highlights Buvidal 30 advantages 19.5 Expanding use in the criminal justice 20
setting 11.0 11.3 10 Wide media coverage of Buvidal
0 Q1 Q2 Q3 Q4 Q1
Quarterly product sales 2019 2020
* Measured by product sales 11
Key access limitations addressed in 2020
Norway Sweden Outreach services started to Reimbursement of Buvidal facilitate patient access and approved by TLV4 mitigate risk of spreading Covid-191 Germany Scotland Physician remuneration Government announced system modified balancing £1.9m budget to support reimbursement for different people in prison on OST to treatment modalities5 switch to Buvidal2 Austria Wales Law changed allowing Wales’ Health Minister injectable treatments 6 supports treatment with Australia for opioid dependence long-acting buprenorphine GPs allowed to during the ongoing prescribe Buvidal Covid-19 crisis3 from 1 April 2020
1. https://sykepleien.no/2020/04/leverer-lar-medisiner-pa-dora?cid=sm7786262328 ; 2. https://news.gov.scot/news/supporting-people-affected-by-drug-use; 3. https://gov.wales/wales-roll-out-once-month-injection-recovering-heroin-addicts-help- protect-nhs-staff; 4. https://www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/arkiv/2020-05-19-buvidal-ingar-i-hogkostnadsskyddet-med-begransning.html; 5. https://www.kbv.de/html/1150_45794.php; 6. Federal law for Austria issued 18 May 2020 Part II 215th regulation: Amendment of the drug regulation 12
Market expansion in Wave 2 countries
Benelux >22,000 patients in opioid Austria 1 dependence treatment >18,000 patients in opioid Preparation for launch dependence treatment1 Launched 19 May 2020 France >179,000 patients in opioid dependence treatment1 Final regulatory Italy discussion with ~70,000 patients in opioid 1 authorities dependence treatment Pricing and reimbursement Spain discussions >58,000 patients in opioid dependence 1 Launch sequence treatment Wave 1 markets Wave 3 markets Preparation for launch Wave 2 markets Wave 4 markets 1. European Drug Report 2019, EMCDDA 13
Global strategy for Buvidal (Brixadi)
REGION PARTNER NO OF PATIENTS PEAK MARKET POTENTIAL
EU ~1.3 million ~€300 million2 Australia HIGH-RISK OPIOID USERS1
North >2 million $0.6-1.2 billion4, 5 America DIAGNOSED WITH OPIOID USE DISORDER IN THE US3
Middle East 5 & North >300,000 €25-75 million 6 Africa (Israel) WITH OPIOID DEPENDENCE
Source: 1European Drug Report 2019; 2Camurus estimate; 3SAMHSA, Results from the 2017 National Survey on Drug Use and Health, Sep. 2018; 4Opioid Use Disorder: Opportunity Analysis and Forecasts to 2027, GlobalData 2018; 5Camurus estimates; 6World Drug Report and NewBridge estimate 14 Regulatory progress with Buvidal® (Brixadi™)
•New regulatory filings •Braeburn preparing for US launch CAM2038 Chronic pain Market authorization application Clear path to final market approval, Pre-submission meeting submitted to the Swiss Agency for after FDA granting Citizen Petition in held with EMA Therapeutic Products (Swissmedic) Nov. 2019 Rapporteurs Market authorization application Request for final FDA approval of the under review in New Zealand NDA for Brixadi accepted by FDA Product positioning & pricing studies under with PDUFA date 1 Dec. 2020 completion All product requirements in place for a Availability of Buvidal in MENA successful launch (Braeburn) Planned 2020 regulatory • submission to EMA region Arbitration proceedings started in England after Camurus issuance of a Early access programs and regulatory material breach notice on Braeburn1 filings initiated with collaboration partner NewBridge Pharmaceuticals FDA final approval of Brixadi expected 1 Dec 2020 – triggering a First patients treated with Buvidal $35 million milestone payment to Camurus
1. Camurus’ press release 15 June 2020 https://mb.cision.com/Main/13456/3134723/1264520.pdf 15
Growing evidence base for Buvidal Key publications1-5
Planned conferences where Buvidal will be presented in 2020
2020
Q1 Q2 Q3 Q4
International ASAM CPDD AAAP Conferences 2-5 Apr 20-24 Jun 10-13 Dec Virtual Virtual San Antonio, USA
ISAM 13-16 Nov Victoria, Canada
European IOTOD Nord Op Sym 24-25 Sept 1-2 Oct Conferences Virtual Uppsala, Sweden
ALBATROS 27-29 Oct Paris, France
National RCGP MDAP SFA Odensee Kon SIPaD RCGP H&J 30-31 Jan 12-13 Mar 6-7 Nov 11-13 Nov 25-26 Nov Conferences London, UK Paris, France Grundlsee, Aut Sorrento, Italy Newcastle, UK
Encephale Fin S Add Med SSA SEPD S Esp San Pen 22-24 Jan 5-6 Mar 5-6 Nov 15-17 Nov 19-21 Nov Paris, France Helsinki, Finland Newcastle, UK Seville, Spain Madrid, Spain
DGS konf Feder SerD J Sociodrog 30 Oct – 1 Nov 18-20 Nov 2-4 Dec Berlin, Germany Rome, Italy Madrid, Spain 1Lofwall et al. JAMA Int. Med. 2018;178(6); 764-773; 2Frost et al, Addiction, 2019;114(8):1416-1426, 3Walsh et al, JAMA Psychiatry 2017;74(9):894-902; 4Haasen, C, et al, J Subst Abuse Treat. 2017;78:22-29; 5Albayaty M, et al, Adv Ther. 2017 34(2):560-575 16 Compelling clinical evidence from head-to-head DEBUT study
•DEBUT – Depot Evaluation Buprenorphine Study met primary endpoint demonstrating superiority Utilization Trial for TSQM global satisfaction1 Difference ‒ Randomized, multi-site, open-label, active-controlled study Scheduled Visit Statistic Buvidal SL BPN SOC† p-value of Buvidal vs standard of care in 120 adult outpatients with (Buvidal - SL BPN) opioid dependence to compare patient reported outcomes Baseline (Mean) 71.2 73.8 - - (PROs) Week 24 (LS Mean) 82.5 74.3 8.2 0.0143 ‒ Primary endpoint: patient reported TSQM† global satisfaction score Treatment period (LS Mean) 82.4 73.8 8.6 0.0016 ‒ Secondary endpoints (selected): other treatment satisfaction domains, treatment burden, quality of life, Primary endpoint First secondary endpoints opioid related behaviors and general health outcomes Global satisfaction Convenience Effectiveness Side Effects score Score Score Score 100 Buvidal Weekly & Monthly CAM2038Buvidal flexible dosing 90 SL BPN * * * * * 80 * Screening R Follow-up period 70 60 n=120 BPN SoC 50
flexible dosing Mean TSQM score 40 w0 w12 w24 w0 w12 w24 w0 w12 w24 w0 w12 w24 Day -28 to -1 Day 1 Week 24 Week 26
1. Lintzeris N, Dunlop A, Haber P, Lubman D, Graham R, Hutchinson S, Hjelmstrom P, Svedberg A, Peterson S, Tiberg F. Results of the DEBUT Study – A Multisite, Open-Label RCT of Weekly and Monthly Depot Buprenorphine Injections (CAM2038) Vs. Daily Sublingual Therapy Investigating Patient Reported Outcomes in Treatment of Opioid Use Disorder. Presented at The College on Problems of Drug Dependence, (CPDD) Virtual Meeting June 22-24, 2020. † Statistically significant p-value ≤ 0.05 TSQM – Treatment satisfaction questionnaire for medication ; SL – sublingual; BPN – buprenorphine; SOC – Standard of Care 17 Further studies continue to expand the Buvidal evidence base
•UNLOC-T – Safety and feasibility of depot •ARIDE – Addiction recovery among opioid- buprenorphine in NSW custodial settings dependent patients treated with injectable ‒ Prospective, non-randomized, open-label, multicenter study in subcutaneous depot buprenorphine 129 OUD patients treated with Buvidal or methadone in 8 prisons ‒ Non-randomized prospective non-interventional 1 observational study with control group design •Results (treatment-as-usual, TAU) performed in Germany The safety profile pf Buvidal was satisfactory with most AEs ‒ ‒ The primary objective is to evaluate quality of life. being mild in severity and no severe treatment related AEs Secondary objectives include satisfaction, illicit ‒ Treatment retention was high (81% at week 16) substance use, social participation and cost- ‒ Treatment costs with Buvidal was ~1/3 of daily methadone and effectiveness. ~1/10 of daily sublingual buprenorphine ‒ Patient recruitment started in March 2020 ‒ Following the study treatment with depot BPN in NSW prisons have expanded rapidly and now include over 640 patients
Buvidal weekly Buvidal monthly Buvidal weekly & monthly
Screening E Screening AS Methadone Extended safety TAU monitoring 1 n=1201 N=426
Day 0 Day 1 Week 4 Week 16 Week 48 Day 1 Month 12
1. Dunlop A, White B, Roberts J, Haber P, Oldmeadow C, Searles A, Cretikos M, Mackson J, Attalla D, Kim S, Murrell T, Doyle M, McEntyre E, Brown L, Howard M, Lintzeris N. Introduction of Long-Acting Depot Buprenorphine in Prison - the UNLOC-T Study. Presented at The College on Problems of Drug Dependence, (CPDD) Virtual Meeting June 22-24, 2020 18
Buvidal is well differentiated
Long-acting injection treatments for opioid dependence
CHOICE OF ROOM CLIN. DATA WEEKLY MONTHLY MULTIPLE SMALL LOW DAY ONE PRODUCT INJECTION TEMP. VS ACTIVE LAUNCHED DOSING DOSING DOSES NEEDLE VOLUMES INITIATION SITES STORAGE CONTROL*
EU, Australia 23G 0.16 – 0.64 mL
US, Canada Australia – – – 19G– 0.5 ––1.5 mL – – –
US – – – 20G– 3.4– mL – – –
*Based on information in product labels 19
Approved medicines and advancing pipeline
Approved medicines Phase 1 Phase 2 Phase 3 Registration Market Buvidal® Opioid dependence
Product candidates Brixadi™ Opioid Dependence1) CAM2038 Chronic pain CAM2029 Acromegaly CAM2029 Neuroendocrine tumors CAM2032 Prostate cancer CAM4072 Genetic obesity disorders2) CAM2043 Pulmonary arterial hypertension CAM2043 Raynaud’s phenomenon 1) Braeburn holds the rights to North America 2) Developed by Rhythm Pharmaceuticals under a CAM4071 Endocrine disorders worldwide license to FluidCrystal® CAM2047 CINV3) 3) CINV – Chemotherapy-induced nausea and vomiting CAM2048 Postoperative pain1)
Medical device episil® Oral liquid
Own approved medicines License collaborations Own product candidates 20
CAM2029 – long-acting subcutaneous octreotide in Phase 3 development
•Innovative medicine in late stage development for rare endocrine disorders and oncology •Designed for enhanced efficacy and patient convenience 21 CAM2029 opportunity addresses key unmet medical needs in the SSA market
•Somatostatin analogues (SSAs) are •CAM2029 offers simplified dosing and US$ billion first-line medical therapy in possibility of self-administration • 2.8 acromegaly and NET ‒ Ready-to-use prefilled syringe or • CURRENT SSA autoinjector for enhanced convenience with MARKET VALUE3 •But there are significant limitations option for self-administration with current SSA treatments •Potential for improved biochemical mUSD ‒ Difficult handling & administration and symptom control SSA annual sales 3000 ‒ Sub-optimal treatment result 2500 ‒ Fast onset and long-acting release Somatuline® Autogel® with 500% higher bioavailability vs Sandostatin® LAR® 2000 octreotide LAR1 1500 Sandostatin® LAR® (octreotide): 1000 ‒ Well maintained or improved biochemical and symptom control indicated with 500 CAM2029 in acromegaly and NET patients2 0
Somatuline® Autogel® (lanreotide): CAM2029:
Source: 1Tiberg F, Br J Clin Pharmacol. 2015 Sep;80(3):460-72; 2.Pavel M et al, Cancer Chemotherapy and Pharmacology 2019; 83:375–385; 3 GlobalData 2020 22 Significant market estimated for CAM2029 in acromegaly and NET
US+EU5 Peak Sales for Acromegaly US+EU5 Peak Sales for NET Scenario 1 CAM2029 is available as a pre-filled syringe (PFS) device with equivalent efficacy to current long- $1,015m acting SSAs, with an assumed $245m penetration of 10–20% in Acromegaly, and 10–15% in NET
$180m $720m Scenario 2 $720m Available both as PFS and as an $180m $145m autoinjector, with equivalent efficacy to current long-acting $435m SSAs and an assumed penetration $485m $120m of 20–25%
Scenario 3 $240m $60m Available both as PFS and as an autoinjector, with data suggesting superior efficacy over current long- acting SSAs, and an assumed higher penetration of 30–35%
Source: 1. Globe Life Sciences reports 2019; data on file CONFIDENTIAL 23 CAM2029 pivotal Phase 3 Acromegaly studies program initiated mid-2019
•Efficacy trial (HS-18-633) •Long-term safety study (HS-19-647) ‒ Phase 3, randomized, double-blind, placebo-controlled, ‒ Phase 3, open-label, single arm, multi-center trial to multi-center trial to assess efficacy and safety of assess the long-term safety of CAM2029 CAM2029 ‒ At least 100 patients exposed to CAM2029 for ‒ Regulatory requirements for efficacy data met 12 months ‒ Roll-over to HS-19-647: efficient and easy for • Roll-over patients from HS-18-633 and patients to continue CAM2029 • ‘New patients’ (partial SSA responders, irradiated ‒ 78 patients, full SSA responders patients, and full SSA responders)
HS-18-633 CAM2029 once monthly HS-19-647 Open-label treatment phase
Screening R Screening Roll-over patients Placebo once monthly from HS-18-633 New patients N=70 Prior treatment N=70 with octreotide N=78, 2:1 Prior treatment or lanreotide with octreotide Rescue with standard of care CAM2029 once monthly or lanreotide
4 - 8 Weeks Day 1 Double-blind treatment phase Week 24 4 - 8 Weeks Day 1 Week 24 Week 52 24
Development timelines for CAM2029
Regulatory submissions Four clinical trials ACRO Phase 3 PC* completed in ACRO healthy subjects ACRO Phase 3 LTSE* and patients characterizing NET Phase 3 PK, PD and safety profile (N=249) New indication Phase 2 Autoinj. PK 2019 2020 2021 2022
ACRO Phase 3 PC ACRO Phase 3 LTSE NET Phase 3 Autoinjector PK Randomized, double- Open-label, long-term Active controlled Phase 3 PK bridging study of blind, placebo- safety study in partial study in patients with prefilled syringe and controlled study in and full responders metastatic, well differen- autoinjector devices SSA responders tiated GEP-NET
*Covid-19 impact • Recruitment of ACRO Phase 3 studies temporarily stalled by Covid-19 outbreak • Expecting recruitment delay • Focus shifted to other time critical activities, including autoinjector development 25
Progress in partnerships
Rhythm collaboration Ra Pharma collaboration Long-acting setmelanotide for Long-acting zilucoplan for treatment of treatment of genetic obesity disorders complement C5 mediated disorders Positive Phase 3 data announced for License agreement signed July 2019 daily setmelanotide in POMC / LEPR deficiency August 20191 Preparations for clinical development ongoing Phase 1b clinical milestone achieved Expected to enter start clinical Plasma half-life ~120 hours2 ‒ development in H2 2020 ‒ Good tolerability Positive Phase 2 results for weekly Early stage collaborations depot announced in June 2020 Two new research collaborations with FDA discussions on registration international pharmaceutical path for long-acting weekly companies initiated during the first setmelanotide being prepared quarter 2020
Source: 1Press release Rhythm Pharmaceuticals 7 August 2019; 2Rhythm Corporate Presentation – January 2020 https://ir.rhythmtx.com/static- files/38f3b5c8-4b34-4fde-935a-2d041bf20696; 26 Strong results and news flow reported and anticipated during 2020
Announcement of strong Start CAM2029 Final market Buvidal demand during autoinjector approval of Q1 2020 bridging PK study Brixadi™ in the US
GPs allowed to prescribe Request for final Start Phase 2 Long-acting Buvidal in Australia market approval to CAM2029 new zilucoplan clinical US FDA indication study start Buvidal launched in Austria MAA submission Results CAM2029 Buvidal reimbursed CAM2038 chronic bridging PK study in Sweden pain to EMA autoinjector
CTA for CAM2043 Strong Phase 2 results Start CAM2043 IND CAM2029 Phase 2 in RP Q1 report long-acting Phase 2 in Raynaud’s Phase 3 study in setmelanotide phenomenon NET 2020 H1 H2 Q12021 27 Multiple levers for growth and value creation on short and medium term
® Buvidal / Brixadi™ Pipeline Corporate Establish leadership in opioid Late-stage development and new Continue to build our dependence treatment regulatory approvals in chronic commercial infrastructure with Buvidal® in Europe and pain, acromegaly and NET and launch new products Australia Grow our pipeline of innovative Develop sustained profitability US market approval and launch of medicines and expand the use of through own sales, partnerships Brixadi™ and continued RoW our FluidCrystal® technology in and business development expansion of Buvidal areas of high unmet need and market potential 28
Appendix
Camurus AB │ Ideon Science Park, SE-223 70 Lund, Sweden
P +46 46 286 57 30 │ [email protected] │ camurus.com 29
Braeburn dispute
•Camurus announced on 15 June that Braeburn has initiated arbitration proceedings in England1 ‒ Camurus previously served a notice of material breach questioning Braeburn’s performance primarily relating to: • Preparations for regulatory approval and commercialization of Brixadi/CAM2038 for OUD in Canada • Preparations for a separate earlier launch of Brixadi weekly product for the treatment of OUD in the US • Preparations for regulatory approval and commercialization of Brixadi for the treatment of chronic pain ‒ Braeburn has disputed the validity of the material breach notice ‒ The license agreement stipulates a 90 days arbitration process •Possible outcomes ‒ If the Tribunal finds that Braeburn is in material breach: • Camurus will be entitled (subject to a 60-day cure period) to terminate the agreement and regain all rights granted to Braeburn ‒ If the Tribunal finds that Braeburn is not in material breach: • The license agreement will remain in full force and effect
1. Camurus press release 15 June 2020 https://mb.cision.com/Main/13456/3134723/1264520.pdf 30
Financial summary Q1 2020
MSEK 2020 (2019) 2019 (2018) Financial Outlook 2020 Jan-Mar Full Year Expected net revenues* Total revenues 49.3 (18.5) 105.6 (49.3) SEK 340 - 380 million whereof product sales of whereof product sales 48.6 (11.0) 72.1 (11.3) SEK 310 - 330 million OPEX 117.3 (99.4) 442.3 (329.8) Expected full year OPEX Operating result -76.9 (-84.4) -360.0 (-287.2) SEK 570 - 610 million *excluding the $35 million milestone Result for the period -61.6 (-67.6) -289.9 (-234.7) for final FDA approval of Brixadi™in the US Result per share, before and after dilution, SEK -1.19 (-1.62) -6.23 (-5.77)
Cash position 291.3 (406.6) 358.7 (134.4)
30 31
Shareholders
Shareholders as of 29 May 2020 Number of shares % of capital % of votes Shareholder distribution Sandberg Development AB 22,200,692 43.0 43.0 Gladiator 3,758,754 7.3 7.3 Fjärde AP-fonden 3,330,676 6.5 6.5 Fredrik Tiberg, CEO 1,703,188 3.3 3.3 Avanza Pension 1,545,278 3.0 3.0 26,9%
Backahill Utveckling 1,176,491 2.3 2.3 43,0% 0,7% 1,100,000 2.1 2.1 Svenskt Näringsliv 0,7% Camurus Lipid Research Foundation 505,250 1.0 1.0 0,8%0,8% Enter fonder 437,561 0.8 0.8 0,8% 0,8% Lancelot Asset Management 435,000 0.8 0.8 2,1% 1,0% 6,5% 7,3% 3,0% Hamrins Stiftelse 425,000 0.8 0.8 2,3% Grenspecialisten Förvaltning 420,870 0.8 0.8 3,3% Nordnet Pensionsförsäkring 371,606 0.7 0.7 Cancerfonden 350,000 0.7 0.7 Other shareholders 13,837,061 26.9 26.9 In total 51,636,858 100.0 100.0 32
Experienced and committed management team
Fredrik Tiberg, PhD Education: M.Sc. in Chemical Engineering, PhD in Fredrik Joabsson, PhD Torsten Malmström, PhD President & CEO Physical Chemistry, Lund University Chief Business Development Chief Technical Officer Officer Head R&D Previous experience: Professor in Physical In Company since: 2002 Chemistry at Lund University, Visiting Professor at In Company since: 2001 In Company since: 2013 Holdings: 1,703,188 shares Oxford University, Institute for Surface Chemistry Holdings: 45,463 shares & Holdings: 45,363 shares & & 220,000 warrants (Section head) 35,000 warrants 8,000 subscription warrants
Eva Pinotti-Lindqvist Education: Bachelor’s of Science in Economics, Annette Mattsson Urban Paulsson Chief Financial Officer Lund University Vice President, Regulatory Vice President Corporate Affairs Dev.& General Counsel Previous experience: EQL Pharma (CFO), Nordic In Company since: 2014 Drugs (Nordic Market Analyst), Poolia (Finance In Company since: 2017 In Company since: 2017 Holdings: 45,363 shares & Consultant) Holdings: 375 shares & 25,000 Holdings: 8,125 shares & 22,891 warrants subscription warrants 115,000 warrants
Richard Jameson Education: Bachelor’s of Science in Applied Agneta Svedberg Chief Commercial Officer Biological Sciences from University West of Vice President, Clinical & England Regulatory Development In Company since: 2016 Previous experience: GM, UK & Nordics for Reckitt In Company since: 2015 Holdings: 20,490 shares & Benckiser (2010 – 2013) and Area Director Europe, Holdings: 11,341 shares & 80,000 warrants Middle East and Africa for Indivior (2013 – 2016). 75,000 subscription warrants 33 Multiple potential revenue streams from Camurus’ business model
Model Business concept Key revenue streams
Own sales Own product Development and commer- • Product sales development and cialization on innovative commercialization specialty pharmaceuticals
Non-clinical and clinical • License payments and Product development in development of novel development milestones partnerships pharmaceutical products • Royalty and sales milestones
Product specific licenses to Formulation design and early Technology • FluidCrystal technology stage product evaluations collaborations Partnerships